7-[(3-chloropyridin-4-yl)oxy]-5-{[2-methoxy-4-(piperazin-1-yl)phenyl]amino}pyrido[3,4-d]pyridazin-4(3H)-one | 1390656-01-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 7-[(3-chloropyridin-4-yl)oxy]-5-{[2-methoxy-4-(piperazin-1-yl)phenyl]amino}pyrido[3,4-d]pyridazin-4(3H)-one
• 英文别名: 7-(3-chloropyridin-4-yl)oxy-5-(2-methoxy-4-piperazin-1-ylanilino)-3H-pyrido[3,4-d]pyridazin-4-one
• CAS: 1390656-01-5
• 化学式: C₂₃H₂₂ClN₇O₃
• 分子量: 479.926
• InChiKey: QYFIUQAMXNKVDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• [EN] BICYCLIC INHIBITORS OF ALK<br/>[FR] INHIBITEURS BICYCLIQUES DE L'ALK
  申请人：ABBOTT LAB

  公开号：WO2012097682A1

  公开（公告）日：2012-07-26

  The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, wherein R1, X, Y, Z, A, B, G1, and n are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as ALK and methods of treating diseases such as cancer.

  本发明涉及公式（1）的化合物或药用可接受的盐，其中R1、X、Y、Z、A、B、G1和n在描述中有定义。本发明还涉及含有上述化合物的组合物，用于抑制蛋白激酶如ALK并治疗癌症等疾病的方法。
• BICYCLIC INHIBITORS OF ALK
  申请人：Vasudevan Anil

  公开号：US20140155389A1

  公开（公告）日：2014-06-05

  The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, wherein R 1 , X, Y, Z, A, B, G 1 , and n are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as ALK and methods of treating diseases such as cancer.

  本发明涉及公式（1）的化合物或药物可接受的盐，其中R1、X、Y、Z、A、B、G1和n在说明书中有定义。本发明还涉及含有所述化合物的组合物，其对抑制激酶如ALK具有用处，以及用于治疗癌症等疾病的方法。
• BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES
  申请人：Vasudevan Anil

  公开号：US20140194418A1

  公开（公告）日：2014-07-10

  Compounds of formula (I) or pharmaceutical acceptable salts are provided, wherein X 1 ˜X 5 , R 1 ˜R 3 , A, B, Z and n are defined in the description. And compositions containing said compounds, and the uses for inhibitors of kinases such as ALK, and the uses for treating cancer thereof are provided.

  提供了公式（I）的化合物或药物可接受的盐，其中X1〜X5，R1〜R3，A，B，Z和n在描述中定义。还提供了含有所述化合物的组合物，以及用于抑制激酶（例如ALK）的用途，以及用于治疗癌症的用途。
• [EN] 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1<br/>[FR] 2-AMINOQUINAZOLINE 7-PHÉNYL SUBSTITUÉE, INHIBITEURS DE HPK1
  申请人：MERCK SHARP & DOHME

  公开号：WO2022098806A1

  公开（公告）日：2022-05-12

  Compounds of the following formula (I); or the pharmaceutically acceptable salts thereof, are inhibitors of haematopoietic progenitor kinase 1 (HPK1) useful in the treatment of diseases or disorders associated with HPK1. Also disclosed herein are uses of these compounds in the potential treatment or prevention of an HPK1-associated disease or disorder. Also disclosed herein are compositions comprising one or more of the compounds. Further disclosed herein are uses of these compositions in the potential prevention or treatment of an HPK1-associated disease or disorder.

  以下公式（I）的化合物或其药学上可接受的盐是血液祖细胞激酶1（HPK1）的抑制剂，可用于治疗与HPK1相关的疾病或紊乱。本文还披露了这些化合物在潜在的治疗或预防HPK1相关疾病或紊乱中的用途。本文还披露了包含一种或多种化合物的组合物。本文还披露了这些组合物在潜在的预防或治疗HPK1相关疾病或紊乱中的用途。
• HPK1 INHIBITORS AND USES THEREOF
  申请人：QILU REGOR THERAPEUTICS INC.

  公开号：US20220389037A1

  公开（公告）日：2022-12-08

  Provided herein is a compound represented by structural formula (I-0) or formula (II): or a pharmaceutically acceptable salt or a stereoisomer thereof useful for treating diseases (such as cancer) that are treatable by inhibiting HPK1 activity.